ADC Therapeutics Provides Financial and Operational Insights for Q3 2025

ADC Therapeutics Reports Third Quarter 2025 Financial Results

ADC Therapeutics, headquartered in Lausanne, Switzerland, has shared its financial outcomes and key operational updates for the third quarter of 2025, reflecting its ongoing commitment to enhancing treatment options for patients through its antibody drug conjugates (ADCs).

Financial Highlights for Q3 2025

The company's net product revenues amounted to $15.8 million for the quarter ending on September 30, 2025. This figure signifies a slight decline compared to $18 million reported during the same period in the previous year. Over the nine-month period for 2025, revenues totaled $51.2 million. This decrease was primarily influenced by a reduction in sales volume, although a rise in sales price and favorable gross-to-net adjustments provided some mitigation.

Research and Development (R&D) expenses were reported at $26.8 million, down from $32.5 million in Q3 2024. This decline is attributed to reduced expenditures on discontinued projects and strategic adjustments in the company’s clinical trials. Conversely, R&D expenses for the first nine months of 2025 rose slightly to $85.8 million, reflecting increased activities related to the prostate-specific membrane antigen (PSMA)-targeting ADC project.

In terms of operational efficiency, Selling and Marketing (S&M) expenses remained stable at $10.7 million, while General and Administrative (G&A) expenses showed a decrease due to lower professional fees, totaling $8.3 million for the quarter.

Ongoing Clinical Trials and Strategic Updates

ADC Therapeutics has observed notable advancements in its clinical trial processes. The company anticipates sharing updated data from the LOTIS-7 trial, which evaluates ZYNLONTA in combination with the bispecific antibody glofitamab. This announcement is expected before the year concludes, along with continued developments related to the LOTIS-5 trial, where topline results are anticipated in the first half of 2026.

Recent presentations, such as those at the 22nd International Workshop on Non-Hodgkin Lymphoma, highlighted the promising efficacy of ZYNLONTA paired with rituximab in patients with relapsed or refractory follicular lymphoma. Among the 55 patients evaluated thus far, the trial reported an overall response rate of 98.2% with a complete response rate of 83.6%. These encouraging results have prompted the trial's expansion to involve 100 patients, enhancing the potential for further insights.

In a strategic move to bolster its operations, ADC Therapeutics completed a private investment in public equity (PIPE) financing, raising $60 million. The funds will facilitate the expansion and ongoing development of ZYNLONTA as the company looks to position itself for a successful launch for second-line diffuse large B-cell lymphoma (DLBCL) treatments in the future.

Financial Forecast and Future Outlook

Looking ahead, ADC Therapeutics remains optimistic about its financial and operational trajectory. The company's management has stated that the strengthened balance sheet, bolstered by the recent financing, promises a cash runway extending well into 2028.

As of the end of Q3 2025, the company reported cash and cash equivalents amounting to $234.7 million. Following the completion of the PIPE financing, this figure could potentially rise to approximately $292.3 million.

In summary, ADC Therapeutics is in a robust position to continue its innovative work in the ADC space. Through prudent financial management and successful clinical trials, the company appears well-prepared to meet the challenges and opportunities that lie ahead in the evolving landscape of oncology treatment.

For further details, ADC Therapeutics management will host a conference call today at 8:30 a.m. ET detailing these results and providing updates on strategic initiatives. Investors and interested parties can access the call through the company's investor relations webpage.

For more information about ADC Therapeutics and its initiatives, visit adctherapeutics.com.